4TEEN4 Pharmaceuticals GmbH

About 4TEEN4 Pharmaceuticals

4TEEN4 Pharmaceuticals GmbH is a biotechnology company based in Hennigsdorf near Berlin. The company was founded on the discovery of circulating Dipeptidyl-Peptidase-3 (cDPP3) as a key driver and biomarker of shock. The focus is on the development of the humanized monoclonal antibody invobenitug (procizumab), which selectively neutralizes cDPP3 and thus stabilizes the renin-angiotensin-aldosteron system. In addition to therapeutic development, 4TEEN4 pursues a biomarker approach for shock prediction and diagnostics as well as a Named-Patient-Program. The clinical program includes a Phase-1b/2a study in patients with cardiogenic shock and elevated cDPP3 levels, the results of which are to be transitioned into a Phase-2/3 study. The management team brings many years of experience from pharmaceutical and biotech companies such as B·R·A·H·M·S, Adrenomed, and Sphingotec.

Site

Hennigsdorf

Processes

Development of a monoclonal antibody (invobenitug/procizumab) against cDPP3, Biomarker-based shock prediction/diagnostics, Named-Patient-Program, Clinical studies (Phase 1b/2a)

Materials

Invobenitug (Procizumab)

Industries

Pharmaceutical Biotechnology, Critical Care / Intensive Medicine, Cardiology

1. 01

   Research and Development

2. 02

   Preclinical Studies

3. 03

   Clinical Studies (Phase 1b/2a)

4. 04

   Named-Patient-Program

5. 05

   Diagnostics/Biomarker Development

Active Ingredient and Research Approach

Location

Inside the production

History

1. Founded on the discovery of circulating DPP3 (cDPP3) as a key driver and biomarker of shock